In 2007, Pfizer subsidiaries Pharmacia & Upjohn Company, Inc., and Pharmacia & Upjohn Company, LLC paid $34.7 million to resolve charges stemming from the off-label marketing of Genotropin — a human growth hormone medicine — and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before that company was acquired by Pfizer in 2003. Pharmacia & Upjohn Company Inc. also pleaded guilty to a single count of offering to an outside vendor remuneration in the form of an award of a contract to manage a Genotropin patient assistance program as an inducement for recommending the purchase of Pharmacia medicines. Pharmacia & Upjohn Company LLC and Pfizer Inc. also entered into a Deferred Prosecution Agreement and a Non-Prosecution Agreement, respectively, with the Department of Justice.